TA Research expects growth in Duopharma's sales in 2024 due ...

Moomoo AI Nov 9, 2023 14:52

TA Research expects growth in Duopharma's sales in 2024 due to APPL contract and resurgence in consumer health. Despite 3Q23 results, RHB Research also retains 'buy' call, noting the brand's potential growth from investments in high-value sectors like oncology and biosimilars.

Duopharma Likely to See Earnings Recovery in 4Q

Disclaimer: The above information does not represent the views of Moomoo Technologies Inc. (MTI) or constitute investment advice related to MTI and its affiliates. Read more

Translate

Report

47K Views

Comment

Moomoo AI

Moomoo AI Official Account

Your AI assistant for discovering investment opportunities.

4501Followers

0Following

9856Visitors